Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 PDAC patients (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival (OS) analysis demonstrated that KRAS mutation stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousef, Abdelrahman, Yousef, Mahmoud, Chowdhury, Saikat, Abdilleh, Kawther, Knafl, Mark, Edelkamp, Paul, Alfaro-Munoz, Kristin, Chacko, Ray, Peterson, Jennifer, Smaglo, Brandon G., Wolff, Robert A., Pant, Shubham, Lee, Michael S., Willis, Jason, Overman, Michael, Doss, Sudheer, Matrisian, Lynn, Hurd, Mark W., Snyder, Rebecca, Katz, Matthew H.G., Wang, Huamin, Maitra, Anirban, Shen, John Paul, Zhao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441514/
https://www.ncbi.nlm.nih.gov/pubmed/37609177
http://dx.doi.org/10.21203/rs.3.rs-3195257/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441514/
https://www.ncbi.nlm.nih.gov/pubmed/37609177
http://dx.doi.org/10.21203/rs.3.rs-3195257/v1

Ejemplares similares